The heavy selling pressure might have exhausted for Cassava Sciences (SAVA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ...

A downtrend has been apparent in Cassava Sciences, Inc. (SAVA) lately with too much selling pressure. The stock has declined 39.5% over the past four weeks. However, given the fact that it is now ...

Charles Schwab Investment Management Inc. cut its stake in shares of Cassava Sciences, Inc. (NASDAQ:SAVA – Free Report) by 11.6% in the 4th quarter, according to its most recent filing with the ...

U.S. stock indices slump amid tariff talks while healthcare sees major developments: J&J faces a $1.6B lawsuit, new FDA approvals, and a $2B ...

The failure of yet another late-stage study on its Alzheimer's disease candidate puts Cassava Sciences in a pickle with ...

The saga of Cassava Sciences' development of Alzheimer's disease therapy simufilam has come to its dismal end. The company has reported top-line data from a second phase 3 trial of the drug ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Cassava Sciences is working on bringing its own Alzheimer’s treatment to market to join the new generation of therapies emerging in the area. The company’s CEO, Rick Barry, recently announced ...